Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3

Antiviral Therapy

Volumn 4, Issue 1, 1999, Pages 35-44

  Revicki, Dennis A ^a   Swartz, Cassandra ^a   Wu, Albert W ^b   Hanbrich, Richard ^c   Collier, Ann C ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; QUALITY OF LIFE; SAQUINAVIR; ZALCITABINE;

EID: 0032942651     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 1987; 317:185-191.
2. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Annals of Internal Medicine 1990; 112:727-737.
3. Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, Antoniskis D, Ho M, Richman DD, Fuchs E et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 1990; 323:1009-1014.
4. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. New England Journal of Medicine 1992; 327:582-587.
5. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG et al. Combination therapy with zidovudine and didanosine compared to zidovudine alone in human immunodeficiency virus type one infection. Annals of Internal Medicine 1993; 119:786-793.
6. Abrams DI, Goldman AI, Launer C, Korvick JA, Neaton JD, Crane LR, Grodesky M, Wakefield S, Muth K, Kornegay S et al. A comparative trial of didanosine or zalcitaoine after treatment with zidovudine in patients with human immunodeficiency virus infection. New England Journal of Medicine 1994; 330:657-662.
7. Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, Remick SC, Salgo MP, Lin AH, Nauss-Karol C et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Annals of Internal Medicine 1993; 118:762-769.
8. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis caranii pneumonia for persons infected with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes 1993; 6:46-55.
9. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium atrium complex. Recommendations on prophylaxis for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. New England Journal of Medicine 1993; 329:898-904.
10. Decks SG, Smith M, Holodniy M & Kahn JO. HIV-1 protease inhibitors: a review for clinicians. Journal of the American Medical Association 1997; 277:145-153.
11. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 1997; 277:1962-1969.
12. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 1987; 317:192-197.
13. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch MS et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. New England Journal of Medicine 1990; 322:91-949.
14. Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding PA, Schooley RT et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. Journal of the American Medical Association 1989; 262:2405-2410.